Kyorin Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12329
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines. The company offers ethical drugs including mucodyne, kipres, desalex, flutiform, pentasa, ketas and uritos. Its ketas product is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders. Kyorin’s kipres is a bronchial asthma and allergic rhinitis therapeutic drug; and pentasa is an agent for ulcerative colitis and chrohn’s disease. It offers consumer healthcare products such as milton and milton CP and OTC drugs. The company collaborates with other companies to develop new medicine. It has operations in the US and Germany. Kyorin is headquartered in Tokyo, Japan.

Kyorin Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Licensing Agreements 23
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
Kyorin Pharma Enters into Licensing Agreement with Merck 24
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28
Kyorin Pharma Enters into Licensing Agreement with Merck 29
Asset Transactions 30
Galderma Acquires Pekiron Cream From Kyorin Pharma 30
Kyorin Pharmaceutical Co Ltd – Key Competitors 31
Kyorin Pharmaceutical Co Ltd – Key Employees 32
Kyorin Pharmaceutical Co Ltd – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Product News 34
11/01/2017: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA 34
10/28/2017: Cleveland Clinic trial on drug shows promise in slowing progressive multiple sclerosis 35
04/25/2017: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 69th Annual Meeting in Boston 36
04/09/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois 38
02/27/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland 39
02/07/2017: MediciNova Announces MN-166 ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston 40
Clinical Trials 41
Oct 26, 2017: MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability 41
Sep 19, 2017: MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence 42
Aug 30, 2017: MediciNova Announces the Abstract from the MN-166 SPRINT-MS Phase 2b Study in Progressive MS – including Top Line Data – was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017 in Paris, France 43
Jun 05, 2017: MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting 44
Feb 06, 2017: MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research 45
Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
Kyorin Pharma Enters into Licensing Agreement with Merck 24
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28
Kyorin Pharma Enters into Licensing Agreement with Merck 29
Galderma Acquires Pekiron Cream From Kyorin Pharma 30
Kyorin Pharmaceutical Co Ltd, Key Competitors 31
Kyorin Pharmaceutical Co Ltd, Key Employees 32
Kyorin Pharmaceutical Co Ltd, Other Locations 33
Kyorin Pharmaceutical Co Ltd, Subsidiaries 33

List of Figures
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Kyorin Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Spark Therapeutics Inc (ONCE):製薬・医療:M&Aディール及び事業提携情報
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • RPM International Inc:企業の戦略・SWOT・財務情報
    RPM International Inc - Strategy, SWOT and Corporate Finance Report Summary RPM International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • OsteoVantage Inc:製品パイプライン分析
    Summary OsteoVantage Inc (OsteoVantage) is a medical device company that develops osteogenic spinal instrumentation technology used in spinal fusion procedures. The company’s INDOS system is an osteogenic spinal instrumentation for use in lumbar spinal fusion procedures. It also offers osteomodulati …
  • Ashley Furniture Industries Inc:企業の戦略・SWOT・財務情報
    Ashley Furniture Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Ashley Furniture Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Applebee’s Restaurants LLC:戦略・SWOT・企業財務分析
    Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report Summary Applebee's Restaurants LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Corvidia Therapeutics:製薬・医療:M&Aディール及び事業提携情報
    Summary Corvidia Therapeutics is a developer of cardiovascular therapies. The company develops cardiovascular therapies leveraging functional genomics. Its pipeline programs are targeted at identifying patients with unique sensitivity to specific biologic pathways, which allows the development of th …
  • Paramount Resources Ltd (POU):企業の財務・戦略的SWOT分析
    Summary Paramount Resources Ltd (Paramount Resources) is an energy company that offers exploration, production, development, and marketing of oil and gas products. The company offers products such s crude oil, fuel oil, natural gas and natural gas liquids. It operates in three segments such as princ …
  • Otto Energy Ltd (OEL):企業の財務・戦略的SWOT分析
    Summary Otto Energy Ltd (Otto Energy) formerly Ottoman Energy Ltd, is an oil and gas company that offers exploration, production, and development of oil and gas properties. The company's products include oil and gas. It operates its exploration properties located in the Offshore Gulf of Mexico such …
  • AWE Ltd (AWE)-石油・ガス分野:企業M&A・提携分析
    Summary AWE Ltd (AWE) is an independent upstream oil and gas company. It focuses on the exploration, production and sale of oil, gas and condensate. The company has a diverse portfolio of upstream assets in Australia, New Zealand, and Indonesia. Its producing assets include BassGas project in Tasman …
  • Comvita Ltd (CVT):企業の財務・戦略的SWOT分析
    Comvita Ltd (CVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Haworth, Inc.
    Haworth, Inc. - Strategy, SWOT and Corporate Finance Report Summary Haworth, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • AnaBios Corp-製薬・医療分野:企業M&A・提携分析
    Summary AnaBios Corp (AnaBios) is a pre-clinical stage contract research organization which carries out drug efficacy studies on human samples. Its products portfolio includes human dorsal root ganglia (hDRG) neuron cultures, human heart tissue samples,human cardiac mesenchymal stem cells, human bra …
  • Recursion Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Recursion Pharmaceuticals Inc (Recursion Pharmaceuticals) is a biotechnology company that develops novel therapies for the treatment of rare genetic diseases. The company’s pipeline products include novel drugs for various diseases such as ataxia-telangiectasia, cerebral cavernous malformati …
  • Noevir Holdings Co Ltd (4928):企業の財務・戦略的SWOT分析
    Noevir Holdings Co Ltd (4928) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Intellipharmaceutics International Inc (IPCI):製薬・医療:M&Aディール及び事業提携情報
    Summary Intellipharmaceutics International Inc (Intellipharmaceutics) is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlled-release and targeted-release oral solid dosa …
  • WCCT Global Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary WCCT Global Inc (WCCT Global) is a contract research organization that offers early drug development and late phase CRO services. The organization provides CRO solutions, clinical development and clinical support services. Its CRO solutions include project management, clinical monitoring, ph …
  • Centamin Plc:企業の戦略・SWOT・財務情報
    Centamin Plc - Strategy, SWOT and Corporate Finance Report Summary Centamin Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bulgarian Energy Holding EAD:企業の戦略的SWOT分析
    Bulgarian Energy Holding EAD - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • London and Quadrant Housing Trust:企業の戦略・SWOT・財務情報
    London and Quadrant Housing Trust - Strategy, SWOT and Corporate Finance Report Summary London and Quadrant Housing Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • SpectraScience Inc (SCIE):企業の製品パイプライン分析2018
    Summary SpectraScience Inc (SpectraScience) is a medical device company, which undertakes the design, development, manufacture and marketing of light-based technology products. The company offers its proprietary WavSTAT Optical Biopsy System to diagnose tissue health optically by using light. This s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆